ZIVO Bioscience, Inc. Enters Into Pilot Program to Expand Production Into Europe, Contracts With Algatek Asturias, S.L.
KEEGO HARBOR, Mich., July 11, 2017 (GLOBE NEWSWIRE) — ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that it has contracted with Algatek, S.L., the Spanish algae technology innovator, to conduct a pilot program using proprietary Algatek production technology. Algatek operates a fully-licensed food-pharma grade facility that will be able to certify ZIVO products and help streamline compliance in the Eurozone and Middle East regulatory environments, expanding potential markets for the Company’s offerings.
Last week, Algatek successfully introduced the ZIVO strain into its production environment at the facility located in Asturias, Spain and will commence scale-up over the next few weeks, when it is expected to cultivate the ZIVO strain in its commercial-scale 96 meter photobioreactors.
View rest of the original article globenewswire.com/news-release/2017/07/11/1042420/0/en/ZIVO-Bioscience-Inc-Enters-Into-Pilot-Program-to-Expand-Production-Into-Europe-Contracts-With-Algatek-Asturias-S-L.html